R. Scott Huennekens Joins Endologix Board of Directors

Vascular disease solutions provider Endologix LLC has appointed R. Scott Huennekens to its Board of Directors.

Huennekens is a medtech CEO, chairperson, entrepreneur, and investor, having worked for numerous companies. Previously, he led Volcano Corp., a developer of minimally invasive therapy guidance in interventional cardiology, from its 2002 startup to IPO, and eventual to its 2015 sale to Philips. Huennekens was awarded E&Y’s entrepreneur of the year award in 2010 and was recognized by Goldman Sachs in 2016, 2017, and 2018 as one of the 100 most intriguing entrepreneurs at its annual Builders & Innovators conference.

Huennekens graduated magna cum laude with a bachelor of science degree in business administration from the University of Southern California and earned an MBA from the Harvard Business School.

“We are delighted to announce Scott Huennekens as the newest member of our board. With Scott’s extensive background in medtech as both an operator and board adviser, he will be a valuable asset to the company as we go forward,” Endologix President/CEO John Liddicoat, M.D., said.

Endologix LLC is a global medical device company that provides therapies for the interventional treatment of vascular disease. Endologix’s therapeutic portfolio includes assorted products in various stages of development that treat diseases with clinically relevant unmet needs. Endologix’s commercial products, including the AFX 2 Endovascular AAA System, ALTO Abdominal Stent Graft System, and the DETOUR System, are designed to treat a range of vascular diseases, from abdominal aortic aneurysms to lower limb peripheral vascular disease. Endologix is wholly owned by Deerfield Management, an investment management firm committed to advancing healthcare through investment, information, and philanthropy. The company has offices and manufacturing sites in Irvine, Milpitas and Santa Rosa, Calif.